www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50 to 70 seconds Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50 to 70 seconds Primary Endpoint: Death/MI at 30 days SYNERGY PCI A Subset analysis of the SYNERGY trial 4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose

www. Clinical trial results.org SYNERGY PCI Death / MI by intent-to-treat analysis at 30 days % Death MIDeath or MI P=NS

www. Clinical trial results.org SYNERGY PCI Bleeding in the intent-to-treat analysis at 30 days % GUSTO severe TIMI major TIMI minor P<0.05

www. Clinical trial results.org SYNERGY PCI Among high-risk ACS patients undergoing PCI, the rate of death/MI at 30 days was not significantly different between patients treated with enoxaparin or unfractionated heparin. Primary endpoint data for PCI patients is consistent with primary SYNERGY trial As in primary SYNERGY trial, enoxaparin was associated with an increase in TIMI major bleeding Among high-risk ACS patients undergoing PCI, the rate of death/MI at 30 days was not significantly different between patients treated with enoxaparin or unfractionated heparin. Primary endpoint data for PCI patients is consistent with primary SYNERGY trial As in primary SYNERGY trial, enoxaparin was associated with an increase in TIMI major bleeding